EGFR and glioblastoma: Another group showed that CAR-redirected NK cells may efficiently target wt EGFR and EGFRvIII to treat GBM, and that intracranial treatment of NK-92-EGFR-CAR cells can effectively inhibit tumor growth, indicating that this is a promising clinical strategy [253].